AGIO - Agios Pharm logo

AGIO

Agios Pharm

Agios Pharmaceuticals discovers and develops medicines targeting cellular metabolism, focusing on hemolytic anemias, sickle cell disease, thalassemia, and rare diseases. Its key products include PYRUKYND and tebapivat, aimed at addressing unmet medical needs.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$846today

Score Overview

1 Year
Score
Net Growth0.36%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth82.01%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.7
Net Growth-125.63%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth2374x
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth-107.23%
Net Trend40%
Net Income Consistency
Rev Growth40.70%
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth-8x
Net Trend31%
Net Income Consistency
Rev Growth284.91%
Rev Trend77%
Revenue Consistency

See the full market ranking โ†’

Agios Pharm fundamental performance

Between 2020 and 2025, revenue declined from $ 203M to $ 54M and net income went from -$ 327M to -$ 412M. Revenue increased in every one of those 5 years; net income in 2.

Between 2015 and 2025, revenue declined from $ 59M to $ 54M and net income went from -$ 117M to -$ 412M. Revenue increased in 8 of those 10 years; net income in 4.

Agios Pharm currently holds a 5-year HDB Score of 4.7 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 34.21โ€”
1 Year2025-08-12
$ 35.38-3.31%
5 Years2021-08-12
$ 44.05-22.34%
10 Years2016-08-12
$ 40.42-15.36%
All Time2013-07-24
$ 31.289.37%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 98M-$ 411M$ 617M
2025$ 54M-$ 412M$ 854M
2024$ 36M$ 673M$ 893M
2023$ 26M-$ 352M$ 776M
2022$ 14M-$ 231M$ 783M
2021$ 41.41K$ 1.60B$ 1.02B
2020$ 203M-$ 327M$ 572M
2019$ 117M-$ 411M$ 564M
2018$ 94M-$ 346M$ 805M
2017$ 43M-$ 314M$ 567M
2016$ 69M-$ 198M$ 573M
2015$ 59M-$ 117M$ 375M
2014$ 65M-$ 53M$ 342M
IPO2013$ 25M-$ 39M$ 166M

Explore beyond AGIO

You're looking at Agios Pharm. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies